Vj. Hruby et Rs. Agnes, Conformation-activity relationships of opioid peptides with selective activities at opioid receptors, BIOPOLYMERS, 51(6), 1999, pp. 391-410
The discovery of endogenous opioid peptides 25 years ago opened up a new ch
apter in efforts to understand the origins and control of pain, its relatio
nships to other biological functions, including inflammatory and other, imm
une responses, and the relationships of opioid peptides and their receptors
to a variety of undesirable or toxic side effects often associated with th
e nonpeptide opiates such as morphine including addiction, constipation, a
variety of neural toxicities, tolerance, and respiratory depression. For th
ese investigations the need for potent and highly receptor selective agonis
ts and antagonists has been crucial since they in principle allow one to di
stinguish unequivocally the roles of the different opioid receptors (mu, de
lta, and kappa) in the various biological and pathological roles of the opi
oid peptides and their receptors. Conformational and topographical constrai
nt aint of the linear natural endogenous opioid peptides has played a major
role in developing peptide ligands with high selectivity for mu, delta, an
d kappa receptors, and in understanding the conformational, topographical,
and stereoelectronic structural requirements of the opioid peptides for the
ir interactions with opioid receptors. in turn, this had led to insights in
to the three-dimensional pharmacophore for opioid receptors. In this articl
e we review and discuss some of the developments that have led to potent, s
elective, and stable peptide and peptidomimetic ligands that are highly pot
ent and selective, and that have delta agonist, mu antagonist, and kappa ag
onist biological activities (other authors in this issue will discuss the d
evelopment of other types of activities and selectivities). These have led
to ligands that provide unique insight into opioid pharmacophores and the c
ritical roles opioid ligands and receptor scan play in pain, addiction, and
other human maladies. (C) 2000 John Wiley & Sons, Inc.